Posts tagged ‘oncology strategy consulting’
Sally Church, PhD has been included in the FierceBiotech Top Voices in Biotech Twittersphere published today.
It is always good to receive recognition of Sally’s expertise in cancer drug development and the way she actively engages in social media (Sally writes as @MaverickNY on Twitter).
The Biotech Twittersphere is a community we are pleased to be part of. It’s where information is shared and discussions take place in real-time about new clinical trial results, and the impact for patients and companies. Sally is widely regarded as an industry expert in oncology/hematology new product development and commercialization.
Thanks FierceBiotech for the recognition!
The Supreme Court decision upholding the Affordable Care Act (ACA) means that the sun did not set on the provisions of the Physician Payment Sunshine Act that were contained within it.
Manufacturers of pharmaceuticals and medical devices will be required to report all payments and transfers of value (e.g. honoraria, consulting fees, travel expenses, meals) made to physicians and teaching hospitals.
The good news for Pharma market research vendors is that anonymous market research, where the sponsoring company does not know the names of the doctors interviewed, does not have to be reported.
Market research is not referred to directly in section 6002 of the ACA, but the “exemption” can be inferred from the definition of “payment or other transfer of value” in the Act:
Such term does not include a transfer of anything of value that is made indirectly to a covered recipient through a third party in connection with an activity or service in the case where the applicable manufacturer is unaware of the identity of the covered recipient.
This makes a lot of sense, after all, how can you potentially influence prescribing if you don’t know who is being paid by your market research vendor.
If you would like to know about our Pharma market research services and how we incorporate thought leader (KOL) insights into our Pharma strategy consulting projects, please contact us.
Amgen’s denosumab has been shown to reduce skeletal related events (SRE) but not improve overall survival (OS) in prostate cancer.
Icarus Consultants’ oncology new product development expert, Sally Church Ph.D looks at the role of RANKL signaling (the target of denosumab) and recent research on its role in the spread of cancer.
You can gain more insight on this interesting topic from Sally’s Pharma Strategy Blog post.